Panagiotis M. Zikos

Patra, ESYE23, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Fever of Unknown Origin Unveiling Bone Marrow Necrosis Secondary to Diffuse Large B-cell Lymphoma.

Fever of Unknown Origin Unveiling Bone Marrow Necrosis Secondary to Diffuse Large B-cell Lymphoma.

Journal: Cureus

Published: September 16, 2025

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Journal: Cancers

Published: February 28, 2025

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.

Journal: British journal of haematology

Published: January 17, 2025

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Journal: Leukemia

Published: July 21, 2023

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.

Journal: American journal of hematology

Published: January 16, 2023

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study.

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study.

Journal: Frontiers in oncology

Published: December 21, 2022

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries.

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries.

Journal: Leukemia

Published: September 04, 2022

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.

Journal: Journal of clinical medicine

Published: March 13, 2021

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: September 24, 2020

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Journal: Therapeutic advances in hematology

Published: July 08, 2020

The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.

The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.

Journal: British journal of haematology

Published: June 06, 2020

Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.

Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.

Journal: Hematological oncology

Published: April 25, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026